浙江大学医学院博士研究生导师简介：黄河

2015-10-27 14:35:45来源：网络

　　42.Luo Y, Zhao Y, Tan Y, Shi J, Han X, Zheng Y, Li L, He J, Xie W, Ye X, Cai Z, Lin M, Huang H*. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia. Leu Res. 35: 1307-1311. 2011. (IF: 2.764)

　　43.Zhao Y, Tan Y, Wu G, Liu L, Wang Y, Luo Y, Shi J, Huang H*. Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia. Int J Hematol. 94: 156-162. 2011. (IF: 1.681)

　　44.Hu Y, Cui Q, Liang B,Huang H* Relapsing hematologic malignancies after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 17(8): 1099-1111. 2011. (IF: 3.94)

　　45.Tan Y, Fu H, Luo Y, Shi J, Ye X, Zheng Y, Xiao H, Hu Y, Huang H*.Haploidentical Allogeneic Haematopoietic Stem Cell Transplantation as Salvage Therapy for Engraftment Failure after Unrelated and Autologous Stem Cell Transplantation: a Case Report and Review of the Literature. J Int Med Res. 39: 950-959. 2011. (IF: 0.958)

　　46.Xiao H, Cao W, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Meng X, Zheng W, Zheng G, Han X, Jin L, Zhang L, Wang Y, Yu X, Cai Z, Lin M, Ye X, Huang H*. Immunosuppressive cytokine gene polymorphisms and outcome after related and unrelated hematopoietic cell transplantation in Chinese population. Biol Blood Marrow Transplant. 17: 542-549. 2011. (IF: 3.940)

　　47.Xiao H, Lai X, LuoY, Shi J, Tan Y, He J, Xie W, Li L, Zhu X, Zhu J, Sun J, Wei G，Jin L，Liu L，Wu K，Yu X, Cai Z, Lin M, Ye X, Huang H*. Relationship between TNFA, TNFB and TNFRII gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in Chinese population. Bone Marrow Transplant. 46: 400-407. 2011. (IF: 3.541)

　　48.Wang C, Yu J, Yuan K, Lan J, Jin C*, Huang H*. Plk1-mediated phosphorylation of PinX1 regulates its stability. Eur J Cell Biol. 89(10): 748-756. 2010. (IF: 3.213)

　　49.Hu Y, Cui Q, Liang B, Huang H*. Donor-derived solid malignancies after hematopoietic stem cell transplantation. Onkologie. 33(4):195-200. 2010. (IF: 1.000)

　　50.Wu G, Zhao Y, Lai X, Luo Y, Tan Y, Shi J, Li L, Zheng W, Zhang J, Hu X, Jin A, He J, Xie W, Ye X, Cai Z, Lin M, Huang H*. The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population. Bone Marrow Transplant. 45: 1514-1521. 2010. (IF: 3.541)

　　51.Zheng W, Guan M, Zhu L, Cai Z, Chung V, Huang H*， Yen Y. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells. Anticancer Res. 30(6): 1921-1930. 2010. (IF: 1.713)

　　52.Dong-Wook Kim*, Shripad D. Banavali, Udomsak Bunworasate, Yeow-Tee Goh, Peter Ganly, Huang H, Ian Irving, Saengsuree Jootar, Hyun-Gyung Goh, Liang-Piu Koh, Wei Li, Tomoki Naoe, Soo-Chin Ng, Visalachy Purushotaman, Harryanto Reksodiputro, Lee-Yung Shih, Jih-Luh Tang, Arinobu Tojo, Jianmin Wang, Raymond Wong. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res. 34(11): 1459-1471. 2010. (IF: 2.764)

　　53.Yu J, Lan J, Wang C, Wu Q, Zhu Y, Lai X, Sun J, Jin C*, Huang H*. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells. Cancer Lett. 291(2): 177-186. 2010. (IF: 4.258)

　　54.Wu G, Zhao Y, Lai X, Yang K, Zhu F, Zhang W, Wang W, Luo Y, Tan Y, Wang Y, Cao W, Huang H*. Distribution of killer-cell immunoglobulin-like receptor genes in Eastern mainland Chinese Han and Taiwanese Han populations. Tissue Antigens. 74(6): 499-507. 2009. (IF: 2.753)

　　55.Wu Q, Hu H, Lan J, Emenari C, Wang Z, Chang K, Huang H, Yao X*. PML3 Orchestrates the Nuclear Dynamics and Function of TIP60. J Biol Chem. 284(13):8747-8759. 2009. (IF: 4.651)

　　56.Luo Y, Lai X, Tan Y, Shi J, Zhao Y, Han X, Zheng G, Zhu X, Sun J, Zheng Y, Wu G, He J, Chen S, Jin A, Xie W, Ye X, Cai Z, Lin M, Huang H*. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia. 23(6):1171-1174. 2009. (IF: 10.164)

　　57.Zhao Y, Liu L, Wang Y, Wu G, Lai X, Cao W, Luo Y, Tan Y, Shi J, Xie W, Ye X, Cai Z, Lin M, Huang H*. Efficacy and Prognosis of Chronic Myeloid Leukemia Treated With Imatinib Mesylate in a Chinese Population. Int J Hematol. 89(4):445-451. 2009. (IF: 1.681)

　　58.Zhao Y, Wu G, Wu K, Liu L, Cao W, Yu X, Luo Y, Shi J, Tan Y, Huang H*. Simultaneous occurrence of variant Philadelphia translocations and ABL mutations in two patients with chronic myeloid leukemia. Leuk Res. 33(7):e85-87. 2009. (IF: 2.764)

　　59.Zheng W, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X, Lin M, Huang H, Cai Z*. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. Leuk Res. 33(12):1615-1618. 2009. (IF: 2.764)

　　60.Qiu L, He J*, Ye X, Xie W, Shi J, Zheng W, Sun J, Zhu X, Cai Z, Huang H, Lin M. Invasive pulmonary fungal infection accompanied by severe hemoptysis in patients with hematologic diseases: a report of nine cases. Int J Hematol. 90(1):108-112. 2009. (IF: 1.681)

　　61.Shi J, Cai Z*, Huang H, Ye X, He J, Xie W, Zhang J, Zhou X, Luo Y, Lin Y, Li L, Zheng W, Wei G, Lin M. Role of CT-guided percutaneous lung biopsy in diagnosis of pulmonary fungal infection in patients with hematologic diseases. Int J Hematol. 89(5):624-627. 2009. (IF: 1.681)

　　发表著作：

　　1.周晋,黄河(主编). 2009.《血液内科学》,第一版，第二版，人民卫生出版社

　　2.黄河(副主编).2009.《2010西医综合考试辅导与模拟试题》，浙江大学出版社.

　　3.黄河(参编).2009.《内科学新进展》，浙江大学出版社

　　4.黄河(副主编).2003.《临床疾病与免疫》，科学出版社

　　5.黄河(参编).2002.《感染微生态学》，人民卫生出版社

　　发明专利：

　　1.名称:抗人骨髓间充质干细胞单克隆抗体ZUF10及应用，专利号：ZL 2005 1 0061032.3; (排名第一)

　　2.名称:抗人骨髓间充质干细胞单克隆抗体ZUC3及应用，专利号：ZL 2005 1 0061033.8; (排名第一)

　　3.名称:抗人骨髓间充质干细胞单克隆抗体ZUB1及应用，专利号：ZL 2005 1 0061034.2; (排名第一)

　　4.名称:抗人骨髓间充质干细胞单克隆抗体ZUE12及应用，专利号：ZL 2005 1 0061035.7; (排名第一)

　　5.名称:抗人骨髓间充质干细胞单克隆抗体ZUB4及应用，专利号：ZL 2005 1 0061036.1; (排名第一)